HONG KONG – Looking to position itself as the biggest player in the rapidly growing traditional Chinese medicine (TCM) market in China, the TCM arm of Chinese state-owned Sinopharm Group is planning on a $1.3 billion acquisition of an industry rival and the sale of a biotech subsidiary to channel resources to the development of its TCM business, a move that will help consolidate the market.
HONG KONG – A Chinese biopharmaceutical company with a newly built facility in Suzhou Industrial Park has completed a series C financing of almost $100 million. The funds will help the company develop and manufacture complex and high-end biologics, including biosimilars.
HONG KONG – A Chinese biopharmaceutical company with a newly built facility in Suzhou Industrial Park has completed a series C financing of almost $100 million. The funds will help the company develop and manufacture complex and high-end biologics, including biosimilars.
HONG KONG – Diversified traditional Chinese medicine (TCM) maker Guangzhou Baiyunshan Pharmaceutical Holdings (HK:0874, SH:600332) plans to raise as much as $1.6 billion through a private sale of new shares to be traded in Mainland China.
HONG KONG – A Korean clinical-stage biotech company that focuses on monoclonal antibodies (MAbs) has inked a second deal in two months with its Chinese partner.
HONG KONG – With the global center of gravity shifting eastward and the world's most populous region increasingly wealthy, it should come as no surprise that Asia is gaining momentum in medical research. This advancement is taking place while the leadership role of the U.S. transforms into an important player in a multipolar research world.
HONG KONG – Diversified traditional Chinese medicine (TCM) maker Guangzhou Baiyunshan Pharmaceutical Holdings (HK:0874, SH:600332) plans to raise as much as $1.6 billion through a private sale of new shares to be traded in Mainland China.
HONG KONG – With the global center of gravity shifting eastward and the world's most populous region increasingly wealthy, it should come as no surprise that Asia is gaining momentum in medical research. This advancement is taking place while the leadership role of the U.S. transforms into an important player in a multipolar research world.
HONG KONG – A Korean clinical-stage biotech company that focuses on monoclonal antibodies (MAbs) has inked a second deal in two months with its Chinese partner.
HONG KONG – The CFDA approved the country's first-ever orally administrated and subtype-selective histone deacetylase inhibitor (HDACi). Patients in China with relapsed or refractory peripheral T-cell lymphoma (PTCL) now have an alternative treatment other than traditional chemotherapy.
